NEW YORK, Aug. 11, 2015 /PRNewswire/ -- Renowned Urologist and Robotic Prostate Cancer Surgeon, Dr. David Samadi, solely offers the revolutionary UroNav Fusion Biopsy System for MRI-Guided Fusion Biopsy in men with an elevated PSA.
Innovated from the company, Invivo, the UroNav brings the power of MRI Guided Biopsy to diagnosing prostate cancer. This technique has tremendously improved the detection and differentiation of high and low-risk prostate cancers. Integrating the use of an MRI makes for a much more accurate diagnosis, especially when it comes to the staging of the prostate cancer.
"We're very pleased to now offer the benefit of this advanced technology to our patients. Men come to us with an elevated PSA and if a biopsy permits, the use of the MRI guides us to target specific areas of the prostate that show potential lesions. As opposed to a random biopsy, fusion biopsy is a much smarter approach to diagnosing the disease and also how aggressive the cancer may be," stressed Dr. Samadi.
The UroNav MR/Ultrasound Fusion Biopsy System is a high-tech MRI system that fuses pre-biopsy MR images of the prostate with ultrasound-guided biopsy images in real time.
UroNav combines electromagnetic tracking and navigation with an onboard computer and a real-time imaging interface in one mobile workstation. As seen in the image above, MR/Ultrasound fusion aligns and registers prior diagnostic MR images with real-time ultrasound images. The red outline displays the segmented prostate anatomy from the MR exam and blue/red "targets" indicate the location of the MR suspicious lesions.
"The main advantage is we can see the entire gland. In a targeted biopsy, MRIs of the suspected cancer fused with real-time ultrasound images create a map of the prostate that enables both urologists and pathologists to pinpoint and test suspicious areas of the prostate region," noted Dr. Samadi. "This close collaboration coupled with the targeted MR/Ultrasound biopsy creates a stronger foundation and starting point for the diagnosis process."
For men currently on watchful waiting, targeted fusion biopsy plays a role in following up any change in the clinical status of the cancer and also detects the need for further intervention or a different treatment.
"We can detect low risk prostate cancer and from there, determine if the patient is a good candidate for definitive treatments and close surveillance," said Dr. Samadi.
"The advantage is that this technique can be done in the office, and is convenient. If you have a high volume prostate, with hard to reach lesions, as a follow-up it can be helpful," said Dr. Samadi.
A recent study from North Shore LIJ Urology Center, tested men with elevated PSA levels using the UroNav MR/Ultrasound Fusion Biopsy System along with TRUS (transrectal ultrasound). The results found a higher prostate cancer detection rate compared to data from other studies testing men with elevated PSA levels using a standard 12-core biopsy. Of the prostate cancers diagnosed, 77% were clinically significant using a targeted fusion biopsy.
Patients with an elevated PSA or newly diagnosed with prostate cancer can contact Dr. Samadi to learn more about the UroNav System and the option of MRI-Guided Biopsy by visiting ProstateCancer911.com and calling 212.365.5000.
SOURCE Dr. David Samadi